

TRIAL RESULTS – 18th August 2021

[Further Positive Topline Results Announced from Ph 1 UV1 Cancer Vaccine Combination Study in Metastatic Melanoma](#)

“The emerging picture is that the UV1-pembrolizumab combination has a strong safety profile and provides consistently high levels of clinical response in advanced melanoma,” said Jens Bjørheim, Chief Medical Officer of Ultimovacs. “This latest data adds to the accumulating body of evidence demonstrating that UV1 is safe and can mobilize the immune system to play a transformative role in the treatment of solid tumors.”

[Adoptive Cell Therapy Plus Checkpoint Inhibitors Show Promise in NSCLC](#)

“These results really give hope to adding cell therapy to the armamentarium for treatment of lung cancer. The TILs give the immune system a boost by providing more T cells to mount an attack, and the checkpoint inhibitor prevents the tumor from inactivating the T cells that infiltrate the tumor,” said Eric Haura, M.D., associate center director of Clinical Science at Moffitt.

[Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer Announced](#)

Secondary endpoints in the DeCidE1 clinical study included an extensive analysis of collected biological samples. Dr Jeremy Graff, Chief Scientific Officer of IMV commented, “The translational analyses provide strong evidence that maveropepimut-S successfully elicits the generation of tumor antigen-specific T cells. Importantly, these analyses affirm the molecular and cellular mechanism of MVP-S based therapy. This data will also inform the discussion and design of a Phase 2 clinical study to be submitted to the FDA.”

[Enhertu significantly improved PFS in DESTINY-Breast03 trial vs. T-DM1 in patients with HER2-positive metastatic breast cancer](#)

Susan Galbraith, Executive Vice President, Oncology R&D, said: “There is a continued need for new options and better outcomes for patients with HER2-positive metastatic breast cancer who often experience disease progression after initial treatment with available standards of care. These transformative progression-free survival results demonstrate the superiority of Enhertu compared to T-DM1, and the encouraging safety data may open future opportunities to bring this benefit to patients in earlier treatment settings.”

[Results of Second IDMC Review of Safety Data from ENVASARC Pivotal Trial Announced](#)

“Envafohimab continues to be well tolerated as a single agent and when combined with Yervoy in refractory sarcoma patients who are enrolled in the ENVASARC trial. We remain on track for the

Independent Data Monitoring Committee to review interim efficacy data in the fourth quarter of this year,” said James Freddo, M.D., TRACON’s Chief Medical Officer.

[Ph 3 study shows Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in 1L DLBCL compared to SoC](#)

“Since 40% of people with DLBCL relapse after initial therapy, achieving meaningful treatment effects in the front-line setting has the potential to be transformative,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This Polivy regimen is the first in two decades to improve progression-free survival in DLBCL compared to the standard of care, and we look forward to sharing these results with health authorities to bring this important potential new treatment option to patients as soon as possible.”